OA12610A - A PDE 4 inhbitor and an anti-cholinergic agent in combination for treating obstructive airways diseases. - Google Patents

A PDE 4 inhbitor and an anti-cholinergic agent in combination for treating obstructive airways diseases. Download PDF

Info

Publication number: OA12610A
Authority: OA; OAPI
Prior art keywords: alkyl; sélective; sait; pde4 inhibitor; anticholinergic agent
Prior art date: 2001-05-25

Application number

OA1200300304A

Other languages

English (en)

Inventor

Roisin A Armstrong

John W Watson

Michael Yeadon

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-25

Filing date

2002-05-24

Publication date

2006-06-09

2001-12-07 Priority claimed from GB0129396A external-priority patent/GB0129396D0/en

2002-05-03 Priority claimed from GB0210240A external-priority patent/GB0210240D0/en

2002-05-24 Application filed by Pfizer filed Critical Pfizer

2006-06-09 Publication of OA12610A publication Critical patent/OA12610A/en

Links

229940121948 Muscarinic receptor antagonist Drugs 0.000 title claims abstract description 43
239000000812 cholinergic antagonist Substances 0.000 title claims abstract description 42
208000027771 Obstructive airways disease Diseases 0.000 title description 8
101100296719 Caenorhabditis elegans pde-4 gene Proteins 0.000 title 1
239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims abstract description 37
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 36
238000011282 treatment Methods 0.000 claims abstract description 21
208000027866 inflammatory disease Diseases 0.000 claims abstract description 14
230000000414 obstructive effect Effects 0.000 claims abstract description 14
LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical class O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 claims abstract description 13
150000001875 compounds Chemical class 0.000 claims description 31
125000000217 alkyl group Chemical group 0.000 claims description 27
239000003795 chemical substances by application Substances 0.000 claims description 22
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
229940110309 tiotropium Drugs 0.000 claims description 12
NVOYVOBDTVTBDX-PMEUIYRNSA-N oxitropium Chemical compound CC[N+]1(C)[C@H]2C[C@@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)[C@H](CO)C1=CC=CC=C1 NVOYVOBDTVTBDX-PMEUIYRNSA-N 0.000 claims description 8
229960000797 oxitropium Drugs 0.000 claims description 8
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 7
125000003342 alkenyl group Chemical group 0.000 claims description 7
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical group O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 claims description 7
229960001888 ipratropium Drugs 0.000 claims description 7
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
-1 wherein thealkyl Chemical group 0.000 claims description 7
229910052739 hydrogen Inorganic materials 0.000 claims description 6
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 6
125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 5
125000003545 alkoxy group Chemical group 0.000 claims description 5
229910052736 halogen Inorganic materials 0.000 claims description 5
150000002367 halogens Chemical class 0.000 claims description 5
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 5
101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 claims description 4
101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 claims description 4
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
125000000623 heterocyclic group Chemical group 0.000 claims description 4
229910052760 oxygen Inorganic materials 0.000 claims description 4
239000001301 oxygen Substances 0.000 claims description 4
239000008194 pharmaceutical composition Substances 0.000 claims description 4
125000006729 (C2-C5) alkenyl group Chemical group 0.000 claims description 3
125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 3
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
125000006833 (C1-C5) alkylene group Chemical group 0.000 claims description 2
125000004399 C1-C4 alkenyl group Chemical group 0.000 claims description 2
101100258328 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) crc-2 gene Proteins 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000004183 alkoxy alkyl group Chemical group 0.000 claims description 2
125000004104 aryloxy group Chemical group 0.000 claims description 2
125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
239000003085 diluting agent Substances 0.000 claims description 2
125000005843 halogen group Chemical group 0.000 claims description 2
229920006395 saturated elastomer Polymers 0.000 claims description 2
229910052717 sulfur Inorganic materials 0.000 claims description 2
239000011593 sulfur Substances 0.000 claims description 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 3
CTCKOPRVSJSTDI-UHFFFAOYSA-N [N]=S(=O)=O Chemical compound [N]=S(=O)=O CTCKOPRVSJSTDI-UHFFFAOYSA-N 0.000 claims 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims 1
125000003118 aryl group Chemical group 0.000 claims 1
208000006673 asthma Diseases 0.000 description 25
239000003814 drug Substances 0.000 description 23
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 22
229940124597 therapeutic agent Drugs 0.000 description 22
238000012360 testing method Methods 0.000 description 20
206010006451 bronchitis Diseases 0.000 description 17
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
201000010099 disease Diseases 0.000 description 16
230000000694 effects Effects 0.000 description 15
210000004027 cell Anatomy 0.000 description 14
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 12
239000000203 mixture Substances 0.000 description 12
150000003839 salts Chemical class 0.000 description 11
206010006482 Bronchospasm Diseases 0.000 description 10
230000003110 anti-inflammatory effect Effects 0.000 description 10
210000001519 tissue Anatomy 0.000 description 10
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
230000007885 bronchoconstriction Effects 0.000 description 9
210000004072 lung Anatomy 0.000 description 9
230000001684 chronic effect Effects 0.000 description 8
206010006458 Bronchitis chronic Diseases 0.000 description 7
206010020751 Hypersensitivity Diseases 0.000 description 7
210000000440 neutrophil Anatomy 0.000 description 7
239000002953 phosphate buffered saline Substances 0.000 description 7
239000011780 sodium chloride Substances 0.000 description 7
239000000243 solution Substances 0.000 description 7
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
206010003645 Atopy Diseases 0.000 description 6
241000700198 Cavia Species 0.000 description 6
108010044467 Isoenzymes Proteins 0.000 description 6
230000004913 activation Effects 0.000 description 6
230000007815 allergy Effects 0.000 description 6
229960002504 capsaicin Drugs 0.000 description 6
235000017663 capsaicin Nutrition 0.000 description 6
208000007451 chronic bronchitis Diseases 0.000 description 6
210000003979 eosinophil Anatomy 0.000 description 6
230000004054 inflammatory process Effects 0.000 description 6
230000005764 inhibitory process Effects 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
206010013975 Dyspnoeas Diseases 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 5
108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 5
229940124630 bronchodilator Drugs 0.000 description 5
238000009472 formulation Methods 0.000 description 5
230000002757 inflammatory effect Effects 0.000 description 5
238000007912 intraperitoneal administration Methods 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
208000000059 Dyspnea Diseases 0.000 description 4
206010014561 Emphysema Diseases 0.000 description 4
206010029379 Neutrophilia Diseases 0.000 description 4
108010058846 Ovalbumin Proteins 0.000 description 4
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 4
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 4
206010036790 Productive cough Diseases 0.000 description 4
239000002253 acid Substances 0.000 description 4
230000009471 action Effects 0.000 description 4
230000001078 anti-cholinergic effect Effects 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000008901 benefit Effects 0.000 description 4
230000036772 blood pressure Effects 0.000 description 4
210000000621 bronchi Anatomy 0.000 description 4
238000011597 hartley guinea pig Methods 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000843 powder Substances 0.000 description 4
239000000047 product Substances 0.000 description 4
210000002460 smooth muscle Anatomy 0.000 description 4
206010001052 Acute respiratory distress syndrome Diseases 0.000 description 3
206010066091 Bronchial Hyperreactivity Diseases 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
208000013616 Respiratory Distress Syndrome Diseases 0.000 description 3
229910000831 Steel Inorganic materials 0.000 description 3
210000001744 T-lymphocyte Anatomy 0.000 description 3
230000001154 acute effect Effects 0.000 description 3
238000007792 addition Methods 0.000 description 3
201000000028 adult respiratory distress syndrome Diseases 0.000 description 3
150000001450 anions Chemical class 0.000 description 3
239000000427 antigen Substances 0.000 description 3
102000036639 antigens Human genes 0.000 description 3
108091007433 antigens Proteins 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
230000036427 bronchial hyperreactivity Effects 0.000 description 3
239000000168 bronchodilator agent Substances 0.000 description 3
230000000572 bronchospasmolytic effect Effects 0.000 description 3
239000012530 fluid Substances 0.000 description 3
208000030603 inherited susceptibility to asthma Diseases 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
201000010659 intrinsic asthma Diseases 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
229910052757 nitrogen Inorganic materials 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
230000002685 pulmonary effect Effects 0.000 description 3
230000011514 reflex Effects 0.000 description 3
230000000241 respiratory effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000004043 responsiveness Effects 0.000 description 3
239000007921 spray Substances 0.000 description 3
239000010959 steel Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
102000004506 Blood Proteins Human genes 0.000 description 2
108010017384 Blood Proteins Proteins 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
206010015866 Extravasation Diseases 0.000 description 2
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
108010063738 Interleukins Proteins 0.000 description 2
102000015696 Interleukins Human genes 0.000 description 2
239000007836 KH2PO4 Substances 0.000 description 2
208000019693 Lung disease Diseases 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
PRQROPMIIGLWRP-UHFFFAOYSA-N N-formyl-methionyl-leucyl-phenylalanin Chemical compound CSCCC(NC=O)C(=O)NC(CC(C)C)C(=O)NC(C(O)=O)CC1=CC=CC=C1 PRQROPMIIGLWRP-UHFFFAOYSA-N 0.000 description 2
CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
AYSYSOQSKKDJJY-UHFFFAOYSA-N [1,2,4]triazolo[4,3-a]pyridine Chemical compound C1=CC=CN2C=NN=C21 AYSYSOQSKKDJJY-UHFFFAOYSA-N 0.000 description 2
OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
125000004450 alkenylene group Chemical group 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
125000004429 atom Chemical group 0.000 description 2
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 2
229940125388 beta agonist Drugs 0.000 description 2
210000003123 bronchiole Anatomy 0.000 description 2
230000003182 bronchodilatating effect Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
210000000038 chest Anatomy 0.000 description 2
238000011161 development Methods 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
230000036251 extravasation Effects 0.000 description 2
238000001640 fractional crystallisation Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
230000035874 hyperreactivity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000008595 infiltration Effects 0.000 description 2
238000001764 infiltration Methods 0.000 description 2
210000004969 inflammatory cell Anatomy 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000002085 irritant Substances 0.000 description 2
231100000021 irritant Toxicity 0.000 description 2
230000000155 isotopic effect Effects 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
239000006249 magnetic particle Substances 0.000 description 2
239000003595 mist Substances 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
239000006199 nebulizer Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 description 2
230000001734 parasympathetic effect Effects 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
230000000750 progressive effect Effects 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
206010039083 rhinitis Diseases 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000002904 solvent Substances 0.000 description 2
208000024794 sputum Diseases 0.000 description 2
210000003802 sputum Anatomy 0.000 description 2
230000001629 suppression Effects 0.000 description 2
238000010998 test method Methods 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 2
BNJMRELGMDUDDB-UHFFFAOYSA-N $l^{1}-sulfanylbenzene Chemical compound [S]C1=CC=CC=C1 BNJMRELGMDUDDB-UHFFFAOYSA-N 0.000 description 1
WYRSGXAIHNMKOL-UHFFFAOYSA-N $l^{1}-sulfanylethane Chemical compound CC[S] WYRSGXAIHNMKOL-UHFFFAOYSA-N 0.000 description 1
QSLPNSWXUQHVLP-UHFFFAOYSA-N $l^{1}-sulfanylmethane Chemical compound [S]C QSLPNSWXUQHVLP-UHFFFAOYSA-N 0.000 description 1
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
125000006701 (C1-C7) alkyl group Chemical group 0.000 description 1
PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 1
YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 1
DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
VLRSADZEDXVUPG-UHFFFAOYSA-N 2-naphthalen-1-ylpyridine Chemical compound N1=CC=CC=C1C1=CC=CC2=CC=CC=C12 VLRSADZEDXVUPG-UHFFFAOYSA-N 0.000 description 1
RTAPDZBZLSXHQQ-UHFFFAOYSA-N 8-methyl-3,7-dihydropurine-2,6-dione Chemical class N1C(=O)NC(=O)C2=C1N=C(C)N2 RTAPDZBZLSXHQQ-UHFFFAOYSA-N 0.000 description 1
229930008281 A03AD01 - Papaverine Natural products 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
208000000884 Airway Obstruction Diseases 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
101800004538 Bradykinin Proteins 0.000 description 1
208000009079 Bronchial Spasm Diseases 0.000 description 1
208000014181 Bronchial disease Diseases 0.000 description 1
125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
125000000041 C6-C10 aryl group Chemical group 0.000 description 1
102000017926 CHRM2 Human genes 0.000 description 1
102000017925 CHRM3 Human genes 0.000 description 1
101150060249 CHRM3 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
239000004429 Calibre Substances 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
108010009685 Cholinergic Receptors Proteins 0.000 description 1
101150012960 Chrm2 gene Proteins 0.000 description 1
206010009126 Chronic respiratory failure Diseases 0.000 description 1
206010009137 Chronic sinusitis Diseases 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
101001098805 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4A Proteins 0.000 description 1
101000988424 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4B Proteins 0.000 description 1
101000988423 Homo sapiens cAMP-specific 3',5'-cyclic phosphodiesterase 4C Proteins 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
108090000978 Interleukin-4 Proteins 0.000 description 1
108010002616 Interleukin-5 Proteins 0.000 description 1
108090001007 Interleukin-8 Proteins 0.000 description 1
102100035792 Kininogen-1 Human genes 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
101710122864 Major tegument protein Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910017621 MgSO4-7H2O Inorganic materials 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241000208125 Nicotiana Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
206010061876 Obstruction Diseases 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
101710148592 PTS system fructose-like EIIA component Proteins 0.000 description 1
101710169713 PTS system fructose-specific EIIA component Proteins 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
208000002200 Respiratory Hypersensitivity Diseases 0.000 description 1
206010057190 Respiratory tract infections Diseases 0.000 description 1
206010070834 Sensitisation Diseases 0.000 description 1
201000010001 Silicosis Diseases 0.000 description 1
PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
239000004147 Sorbitan trioleate Substances 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
101710199973 Tail tube protein Proteins 0.000 description 1
GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
102000034337 acetylcholine receptors Human genes 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000000996 additive effect Effects 0.000 description 1
230000009218 additive inhibitory effect Effects 0.000 description 1
239000000464 adrenergic agent Substances 0.000 description 1
238000011292 agonist therapy Methods 0.000 description 1
230000010085 airway hyperresponsiveness Effects 0.000 description 1
208000037883 airway inflammation Diseases 0.000 description 1
210000005091 airway smooth muscle Anatomy 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
238000001949 anaesthesia Methods 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000001045 blue dye Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000009267 bronchiectasis Diseases 0.000 description 1
102100037092 cAMP-specific 3',5'-cyclic phosphodiesterase 4A Human genes 0.000 description 1
102100029168 cAMP-specific 3',5'-cyclic phosphodiesterase 4B Human genes 0.000 description 1
102100029169 cAMP-specific 3',5'-cyclic phosphodiesterase 4C Human genes 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
210000000845 cartilage Anatomy 0.000 description 1
239000006285 cell suspension Substances 0.000 description 1
230000003833 cell viability Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
RCTFEKPBUAMARW-UHFFFAOYSA-N chembl218053 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)OC)C=2C2=C1C(CC)=NN2C1CCCC1 RCTFEKPBUAMARW-UHFFFAOYSA-N 0.000 description 1
ZMFFNWKGXSCXBM-UHFFFAOYSA-N chembl218641 Chemical compound C1CN(C(=NN=2)C=3C=CN=CC=3)C=2C2=C1C(CC)=NN2C1CCCC1 ZMFFNWKGXSCXBM-UHFFFAOYSA-N 0.000 description 1
CEMQXLVYSIOKKQ-UHFFFAOYSA-N chembl218653 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)Cl)C=2C2=C1C(CC)=NN2C1CCCC1 CEMQXLVYSIOKKQ-UHFFFAOYSA-N 0.000 description 1
OTBUQMMSFVAASQ-UHFFFAOYSA-N chembl374995 Chemical compound C1CN2C(C3CCCC3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 OTBUQMMSFVAASQ-UHFFFAOYSA-N 0.000 description 1
SYLAYNHYQLQFKX-UHFFFAOYSA-N chembl425987 Chemical compound C1CN2C(CC=3C=CC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 SYLAYNHYQLQFKX-UHFFFAOYSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
208000023819 chronic asthma Diseases 0.000 description 1
208000037976 chronic inflammation Diseases 0.000 description 1
208000037893 chronic inflammatory disorder Diseases 0.000 description 1
208000027157 chronic rhinosinusitis Diseases 0.000 description 1
239000002817 coal dust Substances 0.000 description 1
229940125773 compound 10 Drugs 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
230000006378 damage Effects 0.000 description 1
229910052805 deuterium Inorganic materials 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
229940042935 dichlorodifluoromethane Drugs 0.000 description 1
229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
229940112141 dry powder inhaler Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229920001971 elastomer Polymers 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000005713 exacerbation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000004761 fibrosis Effects 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
235000013305 food Nutrition 0.000 description 1
239000007789 gas Substances 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229940050410 gluconate Drugs 0.000 description 1
210000002175 goblet cell Anatomy 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000003128 head Anatomy 0.000 description 1
230000036541 health Effects 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
150000004677 hydrates Chemical class 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
150000005828 hydrofluoroalkanes Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
150000002431 hydrogen Chemical class 0.000 description 1
230000003301 hydrolyzing effect Effects 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
238000010902 jet-milling Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
VNYSSYRCGWBHLG-AMOLWHMGSA-N leukotriene B4 Chemical compound CCCCC\C=C/C[C@@H](O)\C=C\C=C\C=C/[C@@H](O)CCCC(O)=O VNYSSYRCGWBHLG-AMOLWHMGSA-N 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
KNJDBYZZKAZQNG-UHFFFAOYSA-N lucigenin Chemical compound [O-][N+]([O-])=O.[O-][N+]([O-])=O.C12=CC=CC=C2[N+](C)=C(C=CC=C2)C2=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 KNJDBYZZKAZQNG-UHFFFAOYSA-N 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
230000001473 noxious effect Effects 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
238000002638 palliative care Methods 0.000 description 1
229960001789 papaverine Drugs 0.000 description 1
210000005037 parasympathetic nerve Anatomy 0.000 description 1
210000001002 parasympathetic nervous system Anatomy 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
230000007170 pathology Effects 0.000 description 1
WTWWXOGTJWMJHI-UHFFFAOYSA-N perflubron Chemical compound FC(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)Br WTWWXOGTJWMJHI-UHFFFAOYSA-N 0.000 description 1
229960001217 perflubron Drugs 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
206010035653 pneumoconiosis Diseases 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
230000036316 preload Effects 0.000 description 1
238000012545 processing Methods 0.000 description 1
239000003380 propellant Substances 0.000 description 1
230000002285 radioactive effect Effects 0.000 description 1
229940044551 receptor antagonist Drugs 0.000 description 1
239000002464 receptor antagonist Substances 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
230000009153 reflex inhibition Effects 0.000 description 1
230000004648 relaxation of smooth muscle Effects 0.000 description 1
201000004193 respiratory failure Diseases 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
208000020029 respiratory tract infectious disease Diseases 0.000 description 1
238000012552 review Methods 0.000 description 1
HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 1
229950005741 rolipram Drugs 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
230000000391 smoking effect Effects 0.000 description 1
230000029547 smooth muscle hypertrophy Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
235000019337 sorbitan trioleate Nutrition 0.000 description 1
229960000391 sorbitan trioleate Drugs 0.000 description 1
230000002048 spasmolytic effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
230000035882 stress Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
229910021653 sulphate ion Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
229940095064 tartrate Drugs 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
229940038773 trisodium citrate Drugs 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
238000009423 ventilation Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Pulmonology (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

OA1200300304A 2001-05-25 2002-05-24 A PDE 4 inhbitor and an anti-cholinergic agent in combination for treating obstructive airways diseases. OA12610A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29360601P	2001-05-25	2001-05-25
GB0129396A GB0129396D0 (en)	2001-12-07	2001-12-07	Pharmaceutical combination
GB0210240A GB0210240D0 (en)	2002-05-03	2002-05-03	Pharmaceutical combination

Publications (1)

Publication Number	Publication Date
OA12610A true OA12610A (en)	2006-06-09

Family

ID=27256347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200300304A OA12610A (en)	2001-05-25	2002-05-24	A PDE 4 inhbitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.

Country Status (25)

Country	Link
US (1)	US20040147544A1 (pl)
EP (1)	EP1395288A1 (pl)
JP (1)	JP2005508861A (pl)
KR (1)	KR20040007605A (pl)
CN (1)	CN1511042A (pl)
AP (1)	AP2003002909A0 (pl)
BG (1)	BG108382A (pl)
BR (1)	BR0209992A (pl)
CA (1)	CA2446613A1 (pl)
CO (1)	CO5640041A2 (pl)
CR (1)	CR7152A (pl)
CZ (1)	CZ20033150A3 (pl)
EE (1)	EE200300585A (pl)
HU (1)	HUP0400037A2 (pl)
IL (1)	IL158776A0 (pl)
MA (1)	MA27027A1 (pl)
MX (1)	MXPA03010162A (pl)
NO (1)	NO20035204D0 (pl)
NZ (1)	NZ529335A (pl)
OA (1)	OA12610A (pl)
PA (1)	PA8546001A1 (pl)
PL (1)	PL367085A1 (pl)
SK (1)	SK14312003A3 (pl)
TN (1)	TNSN03123A1 (pl)
WO (1)	WO2002096463A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2165768B1 (es)	1999-07-14	2003-04-01	Almirall Prodesfarma Sa	Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
DE10230769A1 (de) *	2002-07-09	2004-01-22	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren
US20040058950A1 (en) *	2002-07-09	2004-03-25	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors
EP1610788A1 (en) *	2003-03-28	2006-01-04	ALTANA Pharma AG	Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases
PT1610787E (pt) *	2003-03-28	2008-04-23	Nycomed Gmbh	Associação sinérgica compreendendo roflumilast e um agente anticolinérgico seleccionado de sais de tiotrópio para o tratamento de doenças respiratórias
ES2413011T3 (es)	2004-02-06	2013-07-15	Meda Pharma Gmbh & Co. Kg	Combinación de anticolinérgicos y glucocorticoides para el tratamiento a largo plazo de asma y EPOC
CA2550848C (en) *	2004-02-06	2013-02-26	Meda Pharma Gmbh & Co. Kg	Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases
AU2005210086A1 (en) *	2004-02-06	2005-08-18	Meda Pharma Gmbh & Co. Kg	Treatment of rhinitis with anticholinergics alone in combination with antihistamines phosphodiesterase 4 inhibitors, or corticosteroids
WO2005102344A1 (ja) *	2004-04-27	2005-11-03	Kyowa Hakko Kogyo Co., Ltd.	医薬組成物
ES2311771T3 (es) *	2004-08-19	2009-02-16	Rottapharm S.P.A.	Derivados en n-fenilbenzamida como farmacos para el tratamiento de la enfermedad pulmonar obstructiva cronica (epoc).
SI1863476T1 (sl)	2005-03-16	2016-05-31	Meda Pharma Gmbh & Co. Kg	Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni
GB0511066D0 (en) *	2005-05-31	2005-07-06	Novartis Ag	Organic compounds
EP2275096A3 (en)	2005-08-26	2011-07-13	Braincells, Inc.	Neurogenesis via modulation of the muscarinic receptors
EP2258357A3 (en)	2005-08-26	2011-04-06	Braincells, Inc.	Neurogenesis with acetylcholinesterase inhibitor
KR100696432B1 (ko) *	2005-08-31	2007-03-19	김용환	건강진단용 팬티
AU2006305620A1 (en) *	2005-10-19	2007-04-26	Ranbaxy Laboratories Limited	Compositions of phosphodiesterase type IV inhibitors
WO2007047978A2 (en)	2005-10-21	2007-04-26	Braincells, Inc.	Modulation of neurogenesis by pde inhibition
EP2314289A1 (en)	2005-10-31	2011-04-27	Braincells, Inc.	Gaba receptor mediated modulation of neurogenesis
PL1971369T3 (pl)	2005-12-21	2010-01-29	Meda Pharma Gmbh & Co Kg	Połączenie R,R-glikopirolanu, rolipramu i budesonidu dla potrzeb leczenia chorób zapalnych
US20100216734A1 (en)	2006-03-08	2010-08-26	Braincells, Inc.	Modulation of neurogenesis by nootropic agents
EP2021000A2 (en)	2006-05-09	2009-02-11	Braincells, Inc.	Neurogenesis by modulating angiotensin
US20100184806A1 (en)	2006-09-19	2010-07-22	Braincells, Inc.	Modulation of neurogenesis by ppar agents
EP2100598A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en)	2008-03-13	2009-09-16	Laboratorios Almirall, S.A.	Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
US20100216805A1 (en)	2009-02-25	2010-08-26	Braincells, Inc.	Modulation of neurogenesis using d-cycloserine combinations
EP2510928A1 (en)	2011-04-15	2012-10-17	Almirall, S.A.	Aclidinium for use in improving the quality of sleep in respiratory patients
WO2013106547A1 (en)	2012-01-10	2013-07-18	President And Fellows Of Harvard College	Beta-cell replication promoting compounds and methods of their use

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5552407A (en) *	1993-06-11	1996-09-03	New York University Medical Center	Anhydroecgonine compounds and their use as anticholinergic agents
MX9709897A (es) *	1995-06-06	1998-03-31	Pfizer	5-6-dihidro-9h-pirazol[3,4-c]-1,2,4-triazol[4,3-a]piridinas triciclicas y el uso de las mismas.
US20020193393A1 (en) *	2001-03-07	2002-12-19	Michel Pairet	Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors

2002
- 2002-05-24 PA PA20028546001A patent/PA8546001A1/es unknown
- 2002-05-24 NZ NZ529335A patent/NZ529335A/en unknown
- 2002-05-24 CN CNA028104986A patent/CN1511042A/zh active Pending
- 2002-05-24 JP JP2002592972A patent/JP2005508861A/ja not_active Withdrawn
- 2002-05-24 WO PCT/EP2002/005726 patent/WO2002096463A1/en not_active Ceased
- 2002-05-24 US US10/478,755 patent/US20040147544A1/en not_active Abandoned
- 2002-05-24 CZ CZ20033150A patent/CZ20033150A3/cs unknown
- 2002-05-24 IL IL15877602A patent/IL158776A0/xx unknown
- 2002-05-24 BR BR0209992-6A patent/BR0209992A/pt not_active IP Right Cessation
- 2002-05-24 KR KR10-2003-7015352A patent/KR20040007605A/ko not_active Ceased
- 2002-05-24 SK SK1431-2003A patent/SK14312003A3/sk not_active Application Discontinuation
- 2002-05-24 CA CA002446613A patent/CA2446613A1/en not_active Abandoned
- 2002-05-24 AP APAP/P/2003/002909A patent/AP2003002909A0/en unknown
- 2002-05-24 EP EP02750977A patent/EP1395288A1/en not_active Withdrawn
- 2002-05-24 HU HU0400037A patent/HUP0400037A2/hu unknown
- 2002-05-24 PL PL02367085A patent/PL367085A1/pl not_active Application Discontinuation
- 2002-05-24 MX MXPA03010162A patent/MXPA03010162A/es unknown
- 2002-05-24 OA OA1200300304A patent/OA12610A/en unknown
- 2002-05-24 EE EEP200300585A patent/EE200300585A/xx unknown
2003
- 2003-07-08 TN TNPCT/EP2002/005726A patent/TNSN03123A1/en unknown
- 2003-11-19 CR CR7152A patent/CR7152A/es not_active Application Discontinuation
- 2003-11-19 CO CO03102140A patent/CO5640041A2/es not_active Application Discontinuation
- 2003-11-20 MA MA27408A patent/MA27027A1/fr unknown
- 2003-11-24 NO NO20035204A patent/NO20035204D0/no not_active Application Discontinuation
- 2003-11-24 BG BG108382A patent/BG108382A/bg unknown

Also Published As

Publication number	Publication date
NZ529335A (en)	2005-09-30
TNSN03123A1 (en)	2005-12-23
PL367085A1 (pl)	2005-02-21
EP1395288A1 (en)	2004-03-10
WO2002096463A1 (en)	2002-12-05
NO20035204D0 (no)	2003-11-24
IL158776A0 (en)	2004-05-12
BG108382A (bg)	2004-12-30
SK14312003A3 (sk)	2004-08-03
EE200300585A (et)	2004-04-15
BR0209992A (pt)	2004-04-06
MXPA03010162A (es)	2004-03-10
CA2446613A1 (en)	2002-12-05
US20040147544A1 (en)	2004-07-29
CN1511042A (zh)	2004-07-07
CO5640041A2 (es)	2006-05-31
KR20040007605A (ko)	2004-01-24
AP2003002909A0 (en)	2003-12-31
MA27027A1 (fr)	2004-12-20
CR7152A (es)	2004-02-23
HUP0400037A2 (hu)	2004-04-28
CZ20033150A3 (cs)	2004-06-16
PA8546001A1 (es)	2003-12-30
JP2005508861A (ja)	2005-04-07

Publication	Publication Date	Title
NZ529335A (en)	2005-09-30	A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
OA12609A (en)	2006-06-09	An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
CA2457717A1 (en)	2003-03-20	Use of compounds in a dry powder inhaler
AU2002351066B2 (en)	2007-10-18	Pharmaceutical combinations of adenosine A-2a and beta-2-adrenergic receptor agonists
OA12736A (en)	2006-06-29	Combination of a selective PDE4 inhibitor and an adrenergic beta-2 receptor agonist.
WO2003047628A1 (en)	2003-06-12	Combination of an adenosine a2a receptor agonist and an adrenergic beta-2 receptor agonist
AU2002344167A1 (en)	2002-12-09	A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
ZA200308602B (en)	2005-02-04	A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases.
KR20030010740A (ko)	2003-02-05	신경변성 질환의 예방 및 치료약
HK1063156A (en)	2004-12-17	A pde4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases
HK1070587A (en)	2005-06-24	Combination of a selective pde4 inhibitor and an adrenergic beta-2 receptor agonist
AU2002316924A1 (en)	2002-12-09	An adenosine A2A receptor agonist and an anticholiergic agent in combination for treating obstructive airways diseases
HK1092381A (en)	2007-02-09	Pharmaceutical combinations of adenosine a-2a and beta-2-adrenergic receptor agonists